San Diego, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) — California BanCorp (the “Company”) (Nasdaq: BCAL), the holding company for California Bank of Commerce, N.A. (the “Bank”), announces that the Bank plans to open a new commercial loan production office at 595 Market Street in downtown San Francisco on October 1, 2026. The new office reflects the Bank’s continued commitment to strategic growth and will expand its commercial banking presence in the Bay Area.

“Establishing a physical presence in San Francisco allows the Bank to better serve the city’s diverse and innovative business community. This new office broadens our reach in Northern California and advances our mission to provide responsive, locally focused commercial banking services to privately held businesses,” said David Rainer, Chairman and CEO of the Company and Bank.

ABOUT CALIFORNIA BANCORP

California BanCorp (NASDAQ: BCAL) is a registered bank holding company headquartered in San Diego, California. California Bank of Commerce, N.A., a national banking association chartered under the laws of the United States (the “Bank”) and regulated by the Office of Comptroller of the Currency, is a wholly owned subsidiary of California BanCorp. Established in 2001 and headquartered in San Diego, California, the Bank offers a range of financial products and services to individuals, professionals, and small to medium-sized businesses through its 14 branch offices and four loan production offices serving California. The Bank’s solutions-driven, relationship-based approach to banking provides accessibility to decision makers and enhances value through strong partnerships with its clients. Additional information is available at www.californiabankofcommerce.com.

INVESTOR RELATIONS CONTACT
ir@bankcbc.com

PLANO, Texas, Sept. 30, 2026 (GLOBE NEWSWIRE) — Integer Holdings Corporation (NYSE: ITGR) (“Integer” or the “Company”), a leading global medical device contract development and manufacturing organization (CDMO), today announced that it has received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with the previously announced acquisition of Integer by an affiliate of investment funds managed by KKR (the “Merger”).

As previously announced on August 3, 2026, Integer and KKR entered into a definitive merger agreement dated as of August 2, 2026 (the “Merger Agreement”) pursuant to which an affiliate of KKR will acquire all of the outstanding shares of Integer for $127 per share in cash (the “Transaction”). The Transaction represents a total enterprise value of approximately $5.7 billion. The termination of the HSR waiting period satisfies one of the conditions required for completion of the Transaction. The Transaction remains subject to approval of Integer stockholders and the satisfaction or waiver of other regulatory approvals and other customary closing conditions. Integer continues to expect the Transaction to close by the end of 2026, subject to the satisfaction of these conditions.

Integer will hold a virtual Special Meeting of Stockholders (the “Special Meeting”) on October 21, 2026 at 9:00 a.m., Central Time, to vote to adopt the Merger Agreement, and approve other related proposals. Stockholders of record as of the close of business on September 8, 2026, are entitled to vote at the meeting. The Integer Board of Directors unanimously recommends that all Integer stockholders vote “FOR” the Merger Agreement and other related proposals.

For more information about the proposed Transaction, including the Merger Agreement, the Merger, and the Special Meeting, please see the definitive proxy statement filed with the Securities and Exchange Commission (the “SEC”) by Integer on September 14, 2026 (the “Definitive Proxy Statement”).

About Integer®
Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMOs) in the world, serving the cardio and vascular, neuromodulation, and cardiac rhythm management markets. As a strategic partner of choice, we advance the goals of our medical device customers through industry-leading engineering and manufacturing, with a relentless commitment to quality, service, and innovation. The Company’s brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net.

Contacts
Integer
Media Relations:
Misty Tippen
misty.tippen@integer.net
469-536-6702

Investor Relations:
Kristen Stewart
kristen.stewart@integer.net
551-337-3973

Cautionary Statement Regarding Forward-Looking Statements

Some of the statements contained in this communication and other written and oral statements made from time to time by us and our representatives are not statements of historical or current fact. As such, they are “forward-looking statements” within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations, and these statements are subject to known and unknown risks, uncertainties and assumptions. Forward-looking statements include, but are not limited to, statements relating to: our goals, plans, and strategic initiatives; long-term growth prospects; maximizing value for our stockholders; and other events, conditions or developments that will or may occur in the future; and timing of any of the foregoing. You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “forecast,” “outlook,” “assume,” “potential” or “continue” or variations or the negative counterparts of these terms or other comparable terminology. These statements are only predictions and are no guarantee of future performance, and investors should not place undue reliance on forward-looking statements as predictive of future results. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary factors and to others contained throughout this communication.

Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements regarding the transactions contemplated by the Agreement and Plan of Merger, by and among the Company, Armstrong Parent, Inc. (“Buyer”) and Armstrong Bidco, Inc. All such forward-looking statements are based upon current plans, estimates, expectations, opportunities and ambitions that are subject to risks, uncertainties, assumptions, and other important factors, many of which are beyond the control of the Company, that could cause actual results to differ materially from those expressed in such forward-looking statements. Key factors that could cause actual results to differ materially include, but are not limited to, the expected timing and likelihood of completion of the Transaction, including the timing, receipt and terms and conditions of any required governmental and regulatory approvals; the occurrence of any event, change or other circumstances that could give rise to the termination of the Transaction; the possibility that the Company’s stockholders may not approve the Transaction; the risk that the parties may not be able to satisfy the conditions to the Transaction in a timely manner or at all; risks related to disruption of management time from ongoing business operations due to the Transaction; the risk that any announcements relating to the Transaction could have adverse effects on the market price of the Company’s common stock; the risk that the Transaction and its announcement could have an adverse effect on the parties’ business relationships and business generally, including the ability of the Company to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers, and on their operating results and businesses generally; the risk of unforeseen or unknown liabilities; customer, stockholder, regulatory and other stakeholder approvals and support; the risk of unexpected future capital expenditures; the risk of potential litigation relating to the Transaction that could be instituted against the Company or its directors and/or officers; the risk associated with third-party contracts containing material consent, anti-assignment, transfer or other provisions that may be related to the Transaction which are not waived or otherwise satisfactorily resolved; significant costs, or expenses incurred in connection with the Transaction; the Buyer’s ability to obtain the necessary financing arrangements set forth in the commitment letters received in connection with the Transaction; certain restrictions contained in the Agreement and Plan of Merger that may impact the Company’s ability to pursue certain business opportunities or strategic transactions; the risk of various events that could disrupt operations, including pandemics, epidemics or other public health crises or severe weather (such as droughts, floods, avalanches and earthquakes), cybersecurity attacks, security threats and governmental response to them, and technological changes; the risks of labor disputes, changes in labor costs and labor difficulties; and the risks resulting from other effects of industry, market, economic, legal or legislative, political or regulatory conditions outside of the Company’s control. All such factors are difficult to predict and are beyond our control, including those detailed in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2025, which was filed with the SEC on February 23, 2026, the Company’s quarterly report on Form 10-Q for the fiscal quarter ended July 3, 2026, which was filed with the SEC on August 4, 2026 and other documents subsequently filed by the Company with the SEC. The Company’s forward-looking statements are based on assumptions that the Company believes to be reasonable but that may not prove to be accurate. Other unpredictable factors not discussed in this communication could also have material adverse effects on forward-looking statements. The Company does not assume an obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements speak only as of the date hereof.

Additional Information and Where to Find It

In connection with the Transaction, the Company filed the Definitive Proxy Statement with the SEC on September 14, 2026. The Definitive Proxy Statement and proxy card have been mailed to Integer’s stockholders of record as of the close of business on September 8, 2026. The Definitive Proxy Statement seeks their approval of the Transaction and other related matters. INTEGER’S STOCKHOLDERS AND INVESTORS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT IN ITS ENTIRETY AND ANY OTHER DOCUMENTS FILED WITH THE SEC IN CONNECTION WITH THE TRANSACTION OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY CONTAIN, OR WILL CONTAIN, IMPORTANT INFORMATION ABOUT THE TRANSACTION AND RELATED MATTERS.

Investors and security holders may obtain free copies of these documents, including the proxy statement, and other documents filed with the SEC by the Company through the website maintained by the SEC at https://www.sec.gov. Copies of documents filed with the SEC by the Company will be made available free of charge by accessing the Company’s website at https://investor.integer.net/financial-information/sec-filings/default.aspx or by contacting the Company via email by sending a message to ir@integer.net.

Participants in the Solicitation

The Company, Buyer and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of the Company in connection with the Transaction under the rules of the SEC. Information about the directors and executive officers of the Company and other persons who may be deemed to be participants in the solicitation of stockholders of the Company in connection with the Transaction and a description of their direct and indirect interests, by security holdings or otherwise, is included in the “The Merger (PROPOSAL 1) – Interests of ITGR’s Directors and Executive Officers in the Merger” and the “Security Ownership of Certain Beneficial Owners and Management” sections of the Definitive Proxy Statement. The Definitive Proxy Statement and other documents may be obtained free of charge from the SEC’s website at www.sec.gov.

No Offer or Solicitation

This communication is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities or the solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

(NASDAQ: CYCU)

MCLEAN, Va., Sept. 30, 2026 (GLOBE NEWSWIRE) — Cycurion, Inc. (NASDAQ: CYCU), a leading provider of cybersecurity, information technology, and public safety solutions, today announced that Chairman and Chief Executive Officer L. Kevin Kelly participated in a featured interview with SmallCapVoice.com, Inc., where he discussed the Company’s recent operational milestones, including its largest contract award to date, the acquisition of Digital Ally’s Video Solutions business, expansion within the public safety sector, and Cycurion’s long-term growth strategy.

During the interview, Kelly highlighted Cycurion’s previously announced $54.6 million, 10-year contract award, the largest in the Company’s history, secured through a leading global consulting firm. The contract supports the modernization and secure operation of a major state Health and Human Services system and is expected to generate more than $5 million in annual revenue, with work scheduled to commence in November 2026.

Kelly noted that this landmark award underscores Cycurion’s growing industry reputation, deep cybersecurity expertise, and long-standing client relationships, further validating the Company’s ability to deliver mission-critical security solutions at scale.

cycu thumb 2

The full interview is available here: https://youtu.be/wZBAElMDjF8

“We believe this contract validates both the quality of our people and the evolution of Cycurion’s strategic positioning in the market,” said Kelly. “As we continue moving toward larger, higher-value opportunities, we are seeing increased demand for our specialized cyber capabilities and a growing recognition of the value we bring to major enterprises and government engagements.”

Kelly also discussed Cycurion’s acquisition of Digital Ally’s Video Solutions business, which adds an established public safety technology portfolio, approximately $5.5 million in annual revenue, more than $1.2 million in EBITDA, an installed customer base of over 800 law enforcement agencies, and a portfolio of intellectual property assets. Upon the closing, Cycurion’s pro forma gross revenue run rate stands at approximately $30 million.

“The Digital Ally acquisition is an important step in expanding our public safety ecosystem,” Kelly said. “The transaction adds recurring revenue, attractive margins, valuable technology assets, and significant cross-selling opportunities. By combining advanced public safety technologies with Cycurion’s cybersecurity expertise, we believe we can deliver differentiated solutions that address the evolving needs of law enforcement, emergency services, transportation, and critical infrastructure clients.”

The interview also explored Cycurion’s expanding public safety footprint, including recent municipal and state-level engagements. According to Kelly, public safety continues to serve as a strategic foundation for the Company’s broader expansion into federal government and commercial cybersecurity markets.

“Public safety remains a critical growth area for Cycurion,” Kelly added. “These engagements provide long-term relationships, recurring revenue opportunities, and a platform to introduce additional cybersecurity and technology solutions. At the same time, we are continuing to pursue larger federal opportunities while building new commercial offerings designed to accelerate growth and improve margins.”

Kelly further discussed Cycurion’s strategic vision, including plans to expand its offensive cybersecurity capabilities through new technologies designed to identify vulnerabilities before organizations are breached.

“As cyber threats continue to evolve, organizations are looking beyond traditional defensive solutions,” Kelly said. “We are investing in next-generation capabilities that help customers identify and address vulnerabilities proactively. We believe this approach positions Cycurion to capitalize on emerging opportunities across both government and commercial sectors.”

Looking ahead, Kelly reiterated management’s focus on profitable growth, operational execution, and increasing shareholder value.

“We have made significant progress strengthening the Company’s financial foundation, reducing debt, improving margins, securing long-term contract visibility, and expanding our technology portfolio,” Kelly concluded. “Our team remains focused on execution, and we believe the initiatives currently underway position Cycurion for continued growth as we work toward our long-term objectives.”

About Cycurion

Based in McLean, Virginia, Cycurion (NASDAQ: CYCU) is a forward-thinking provider of AI-enabled IT cybersecurity solutions, committed to delivering secure, reliable, and innovative services to clients worldwide. Specializing in cybersecurity, program management, and business continuity, Cycurion harnesses its AI-enhanced ARx platform and expert team to empower clients and safeguard their operations. Along with its subsidiaries, Axxum Technologies LLC, Cloudburst Security LLC, and Cycurion Innovation, Inc., Cycurion serves government, healthcare, and corporate clients committed to securing the digital future. For more information, visit www.cycurion.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Such statements include, but are not limited to, the expected revenue, EBITDA and other anticipated financial and operational benefits arising from the acquisition of the Digital Ally video solutions business (the “Business”); statements regarding the anticipated commercial benefits of the Company’s patents, including expected expansion of the Company’s customer base and expected effects on customer retention; statements regarding the scope, validity, enforceability, and remaining term of the Company’s issued patents; statements regarding the availability of the patented functionality across the Company’s installed base of deployed systems; statements regarding the number of client relationships acquired in the Business; statements regarding the Company’s pro forma gross revenue run rate; statements regarding the Company’s execution of its strategic plan; the anticipated benefits, timing, and integration of pending or completed acquisitions; the performance of and revenue expected from government and commercial contracts; the development and commercialization of the Company’s AI-enabled cybersecurity platforms, including ARx; the Company’s expectations regarding its path to profitability; the Company’s ability to regain or maintain compliance with the continued listing standards of the Nasdaq Stock Market; and the conduct, timing, and outcome of the Company’s investigations and any related legal proceedings. Forward-looking statements may be accompanied by words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “will,” and similar expressions.

Forward-looking statements are based on management’s current expectations and assumptions and involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied, many of which are outside the Company’s control and difficult to predict. These risks include, but are not limited to: the Company’s ability to develop, market, and sell products incorporating the patented technology; the possibility that the patented technology does not increase customer retention or expand the Company’s customer base as anticipated; the outcome of the Company’s investigations and any legal proceedings the Company may initiate or become subject to, and the costs, time, and resources associated with such matters; the Company’s ability to identify, finance, complete, and integrate acquisitions; risks relating to the Company’s intellectual property, including that issued patents may be challenged, narrowed, invalidated, or designed around, that they may not provide meaningful competitive advantage or barriers to entry, and that third parties may assert infringement claims against the Company; the Company’s ability to win, retain, and perform under government and commercial contracts; the Company’s need for additional capital and the terms on which it may be available; the Company’s ability to satisfy Nasdaq’s continued listing requirements; competitive conditions and technological change in the cybersecurity market; and volatility in the trading price and volume of the Company’s common stock, which may occur for reasons unrelated to the Company’s operating performance. Additional risks and uncertainties are described in the Company’s most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

Forward-looking statements speak only as of the date of this press release. Except as required by law, the Company undertakes no obligation to update any forward-looking statement.

Cycurion Investor Relations:
(888) 341-6680
investors@cycurion.com

Cycurion Media Relations:
(888) 341-6680
media@cycurion.com

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/566c30d8-ff54-4476-8120-00364fd810bc

A video accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/5ed1a647-4348-478a-a5a5-04c9acfefe74

– Analysis shows YCANTH achieved complete clearance of molluscum contagiosum approximately 4 times faster than vehicle, regardless of disease duration –

WEST CHESTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will present posters on a new analysis of Phase 3 trials of YCANTH® (VP-102) and an encore presentation of data from a Phase 2 trial of VP-315. Verrica will present at the Fall Clinical Dermatology Conference (October 8–11, Wynn Las Vegas, Las Vegas, NV) and at the 2026 PeDRA Annual Conference (October 15–17, Alexandria, VA).

“We remain highly encouraged by the continued generation of clinical evidence supporting our dermatology portfolio,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. “These new pooled data from the CAMP-1 and CAMP-2 Phase 3 trials reinforce VP-102’s profile as the new standard of care for molluscum contagiosum, showing that patients may achieve complete clearance of their molluscum lesions approximately four times faster than with vehicle, regardless of how long patients have had the disease. In addition, three times as many patients treated with YCANTH achieved complete clearance versus vehicle at each time point measured during the two trials, which reflects the consistent and durable treatment effects of YCANTH. We believe this new analysis provides physicians further confidence to treat patients with YCANTH as soon as a diagnosis is made, rather than defaulting to a ‘watch and wait’ approach typically employed by healthcare professionals before an FDA-approved option existed for patients.”

“We continue to analyze the YCANTH data to help us better understand its ability to reduce the impact of disease upon patients, and accelerate their return to normal activities,” added Noah L. Rosenberg, M.D., Chief Medical Officer of Verrica. “This data, demonstrating more rapid complete clearance with YCANTH, independent of disease duration, gives clinicians a clear, data-driven rationale for early intervention rather than watchful waiting.”

About the Posters:

VP-102 Achieved Complete Clearance Approximately 4 Times Faster Than Vehicle, Regardless of Disease Duration

The Company will present results from a post-hoc pooled analysis of two completed Phase 3 trials of YCANTH for the treatment of molluscum contagiosum (molluscum), evaluating time to first complete clearance and the impact of disease duration on treatment response.

Key new findings include:

  • Subjects treated with VP-102 achieved complete clearance at an approximately 4-fold faster rate than vehicle (HR=4.06; 95% CI, 2.94–5.74), with treatment-effect estimates ranging from 4.05 to 4.19 across sensitivity analyses.
  • Kaplan-Meier cumulative complete clearance by Day 84 was 60.1% with VP-102 versus 19.9% with vehicle.

Potential Abscopal Effect of VP-315 in Untreated Basal Cell Carcinoma Tumors

Verrica will present an encore poster, previously presented at the 2026 Society for Investigative Dermatology (SID) Annual Meeting, describing an exploratory analysis of potential abscopal-like effects of VP-315, the Company’s investigational oncolytic peptide immunotherapy, in patients with basal cell carcinoma (BCC). The analysis examined untreated, non-target lesions (NTLs) in subjects from Part 2 of a Phase 2 multicenter study following intratumoral treatment with VP-315 of separate target lesions.

Presentation Details

2026 Fall Clinical Dermatology Conference | October 8–11, 2026 | Wynn Las Vegas, Las Vegas, NV

  • Poster: VP-102 Demonstrates More Rapid Complete Clearance of Molluscum Contagiosum Regardless of Disease Duration: A Pooled Analysis of Two Phase 3 Trials
    Convention/Meeting Space: Cristal Ballrooms 1, 3, 5, 7
    Time of Poster Session:
    • Friday, October 9th, 7:00 am – 6:00 pm PDT with Scientific Poster Review session from 4:00 pm -5:00 pm PDT
    • Saturday, October 10th, 7:30 am – 12:30 pm PDT (Exhibits and Poster Gallery Open)
    • Sunday, October 11th, 7:00 am – 1:00 pm PDT (Poster Gallery Open)
  • Poster: VP-315 Demonstrates a Potential Abscopal Effect in Untreated Non-Target Basal Cell Carcinoma (BCC) Tumors (Encore)
    Convention/Meeting Space: Cristal Ballrooms 1, 3, 5, 7
    Time of Poster Session:
    • Friday, October 9th, 7:00 am – 6:00 pm PDT with Scientific Poster Review session from 4:00 pm -5:00 pm PDT
    • Saturday, October 10th, 7:30 am – 12:30 pm PDT (Exhibits and Poster Gallery Open)
    • Sunday, October 11th, 7:00 am – 1:00 pm PDT (Poster Gallery Open)

2026 PeDRA Annual Conference | October 15–17, 2026 | Alexandria, VA

  • Poster: VP-102 Demonstrates More Rapid Complete Clearance of Molluscum Contagiosum Regardless of Disease Duration: A Pooled Analysis of Two Phase 3 Trials
    Convention/Meeting Space: Hilton Alexandria Mark Center
    Time of Poster Session: October 15-17, 2026 (Poster Reception Thursday, October 15th at 5:00 pm EDT)

About YCANTH® (VP-102)

YCANTH® is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum. YCANTH is the first and only healthcare professional-administered product approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. Please visit YCANTHPro.com for additional information.

YCANTH is now approved for the treatment of molluscum contagiosum in Japan based upon an additional Phase 3 trial of approximately 300 patients. YCANTH is being studied in a global Phase 3 program in the US and Japan for use in the treatment of common warts.

About VP-315 (ruxotemitide)

VP-315 is a potential first-in-class oncolytic chemotherapeutic peptide immunotherapy administered directly into a tumor to induce immunogenic cell death and thereby unleashing a broad spectrum of tumor antigens for T cell responses, which may offer a non-surgical option for patients suffering from skin cancer. The technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. Verrica holds an exclusive worldwide license to develop and commercialize VP-315 for certain dermatologic oncology indications, including non-metastatic melanoma and non-metastatic merkel cell carcinoma, and intends to focus initially on basal cell and squamous cell carcinomas as the lead indications for development. VP-315 has demonstrated positive tumor-specific immune cell responses in multi-indication Phase 1/2 oncology trials.

About Verrica Pharmaceuticals Inc.

Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma ASA to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include statements about the clinical development and potential benefits of Verrica’s product candidates, including YCANTH (VP-102) and VP-315, and the data described in this press release. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include risks and uncertainties related to market conditions and other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended December 31, 2025, Verrica’s Quarterly Reports on Form 10-Q and other filings Verrica makes with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

John Kirby
Interim Chief Financial Officer
jkirby@verrica.com

Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com

POMPANO BEACH, Fla., Sept. 30, 2026 (GLOBE NEWSWIRE) — BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that it has entered into definitive agreements for the issuance and sale of 735,296 shares of the Company’s common stock, Series A warrants to purchase up to an aggregate of 735,296 shares of common stock and Series B warrants to purchase up to an aggregate of 735,296 shares of common stock, at a purchase price of $4.08 per share and associated warrants in a private placement priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $3.83 per share and will be exercisable immediately upon issuance. The Series A warrants will expire five years after the effective date of the Resale Registration Statement (as defined below) and the Series B warrants will expire twenty-four months after the effective date of the Resale Registration Statement.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The aggregate gross proceeds to the Company from the offering are expected to be approximately $3 million, before deducting placement agent fees and other offering expenses. If the Series A and Series B warrants are exercised in full for cash, the Company would receive additional gross proceeds of approximately $5.6 million. There can be no assurance that any of the warrants will be exercised. The offering is expected to close on or about September 30, 2026, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.

The securities described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”) and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants sold in the offering, have not been registered under the Act or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. Pursuant to a registration rights agreement, the Company has agreed to file one or more registration statements with the SEC covering the resale of the shares of common stock to be issued in the offering and issuable upon exercise of the warrants to be issued in the offering (the “Resale Registration Statement”).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About BioStem Technologies, Inc. (Nasdaq: BSEM):

BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.

BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established in compliance with current Good Tissue Practices (“cGTP”) and current Good Manufacturing Practices (“cGMP”). BioStem’s portfolio of quality brands includes its Neox®, Clarix®, VENDAJE® and American Amnion™ product lines.

Forward-Looking Statements:

Certain statements in this press release may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate”, “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements in this press release include, without limitation, statements regarding the completion of the offering, the satisfaction of customary closing conditions related to the offering, the potential exercise of the warrants and the intended use of net proceeds from the offering.

Forward-looking statements with respect to strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: the Company’s ability to maintain compliance with Nasdaq’s continued listing standards; the Company’s ability to obtain financing on terms acceptable to it, or at all; the impact of any changes in applicable laws or regulations; the Company’s accounts receivable collection risk and concentration; the Company’s ability to maintain production of its products in sufficient quantities to meet demand; and the possibility that the Company may be adversely affected by other general economic, business, and/or competitive factors. There may be additional risks about which the Company is presently unaware of or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company undertakes no duty to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign up for the Company’s email distribution list HERE, and follow us on X and LinkedIn.

Contact BioStem:
Website: www.biostemtechnologies.com
E-Mail: pr@biostemtech.com
X: @BSEM_Tech
Facebook: BioStemTechnologies
Phone: 954-380-8342

Investor Relations:
Philip Trip Taylor, Gilmartin Group
ir@biostemtech.com

SINGAPORE, Sept. 30, 2026 (GLOBE NEWSWIRE) — HomesToLife Ltd (Nasdaq: HTLM) (“HomesToLife” or the “Company”), a Singapore-based home furniture company with sales across Asia-Pacific, Europe and North America, today announced its unaudited financial results for the six months ended June 30, 2026 (“1H 2026”).

Key Financial Highlights
 
    1H 2025
US$’000
    1H 2026
US$’000
    Change  
Net revenue   180,775     198,305     10 %
Retail   3,382     5,314     57 %
Export   168,009     186,293     11 %
Leather Trading   9,383     6,698     (29 %)
By geographical   180,775     198,305     10 %
Asia Pacific   48,683     46,680     (4 %)
Europe   109,989     123,660     12 %
North America   22,103     27,966     27 %
Gross profit   49,833     56,994     14 %
Gross profit margin   27.6 %   28.7 %   1.1 pp
Operating expenses   (40,784 )   (47,295 )   16 %
Sales and distribution expenses   (31,092 )   (36,967 )   19 %
General and Administrative expenses   (9,692 )   (10,328 )   7 %
Income from operations   9,048     9,698     7 %
Net income   10,024     6,068     (39 %)
Earnings per share (Basic and diluted)   0.11     0.07     (39 %)
 

Financial results for the six months ended June 30, 2025 (“1H 2025”) and 1H 2026, unless otherwise stated, reflect the inclusion of HTL Marketing Pte. Ltd. (“HTL Marketing”) because of the acquisition of 100% of equity interests in HTL Marketing completed on May 19, 2025.

1H 2026 Performance

In 1H 2026, the Company delivered strong net revenue of US$198.3 million, representing a year-on-year increase of 10%, driven by a US$18.3 million increase in export sales. By region, net revenue from North American and Europe markets saw 27% and 12% growth respectively compared to 1H 2025, while Asia Pacific market experienced a slight decline by 4%. Retail sales continued to support the revenue growth with a 57% year-on-year increase, attributable to the expansion of the retail stores and retail sales growth in South Korea.

Gross profit rose 14% from US$49.8 million in 1H 2025 to US$57.0 million in 1H 2026, with margins expanding by 1.1 percentage points. The continuous growth was primarily attributable to a favorable shift in sales mix, along with the better sales performance in both Europe and North America. Operating expenses increased by US$6.5 million due to higher selling expenses along with larger sales volumes and increased freight and logistics costs.

Income from operations reached US$9.7 million in 1H 2026, rising by 7% from US$9.0 million in 1H 2025. In the meantime, net income decreased from US$10.0 million in 1H 2025 to US$6.1 million in 1H 2026, primarily resulting from a net foreign exchange loss of US$2.2 million during the reporting period, compared with a foreign exchange gain of US$4.3 million in the same period last year. Excluding foreign exchange gain (loss), net income would have increased by 22% from US$6.5 million in 1H 2025 to US$7.9 million in 1H 2026. Earnings per share stood at US$0.07 in 1H 2026.

Financial Position

Cash outflows from operating activities improved with a reduction from US$11.3 million in 1H 2025 to US$8.3 million in 1H 2026, representing a year-on-year decrease of 26%. Net cash used in investing activities amounted to US$2.0 million, and net cash provided by financing activities amounted to US$1.5 million during the reporting period.

As of June 30, 2026, the Company maintained a healthy liquidity position, as cash and cash equivalents totalled US$17.9 million after US$5.8 million dividend payments and short-term borrowings reduced to US$7.3 million as of June 30, 2026 from US$10.4 million as of December 31, 2025. Net current assets were US$18.3 million, underscoring the Company’s positive working capital profile.

Outlook

HomesToLife expects to maintain stable sales growth for the remainder of FY2026, in line with its earlier guidance of US$400 million to US$420 million for the full year. Building on its growing export business and diversified revenue base, the Company will remain focused on enhancing operational efficiency, prudent cost management, and working capital optimization to support sustainable long-term growth.

The Company will also continue to closely monitor external factors that may affect operating performance, including foreign exchange movements, logistics costs, raw material prices, and broader macroeconomic as well as geopolitical developments. While foreign exchange movements affected reported net income during the reporting period, the Company continues to actively manage its foreign-exchange exposure through natural hedges and risk-management measures while maintaining its geographically diversified operations, helping to mitigate the impact of currency volatility and support resilient business performance.

“The first half of 2026 demonstrated the strength of our business fundamentals and the benefits of our diversified global strategy,” said Ms. Phua Mei Ming, Chief Executive Officer of HomesToLife. “While we remain mindful of ongoing market uncertainties, we are optimistic about the opportunities ahead. We will continue to proactively manage risks, invest in product innovation, and strengthen our presence across key markets.”

The Company remains in progress with its proposed secondary listing (“Proposed Secondary Listing”) on the Main Board of the Singapore Exchange Securities Trading Limited (the “SGX-ST”). The Proposed Secondary Listing remains subject to regulatory review and approval, and if approved, the fulfilment of certain conditions and other applicable listing requirements.

About HomesToLife Ltd (Nasdaq: HTLM)

HomesToLife Ltd is a global furniture company headquartered in Singapore. Leveraging 50 years of heritage built by its founders, the Company combines wholesale distribution, consumer retail, and sourcing capabilities, supported by a diversified sourcing and supplier network across China, Vietnam and India.

The Company operates through three core business divisions: (i) export division for supplying furniture to wholesale customers such as retailers and distributors worldwide, (ii) leather trading division and (iii) retail division with direct retail operations in Singapore and South Korea.

Across these business divisions, the Company operates an integrated supply chain model that encompasses product design and development, sourcing from the Company’s manufacturing partners, and the coordination of logistics and distribution channels. This operating model enables the Company to translate designs into production-ready products efficiently, supporting both branded and white-label offerings, and allows the Company to deliver scale and consistency across multiple markets.

The Company is fast expanding across Europe, Asia-Pacific, and North America, leveraging an integrated supply chain model and a global presence to deliver scale and consistency across multiple markets.

FORWARD-LOOKING STATEMENTS

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and similar statements. Statements that are not historical facts, including statements about the Company’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

CAUTIONARY STATEMENT

The Proposed Secondary Listing remains subject to regulatory review and approval, and if approved, the fulfilment of certain conditions and other applicable listing requirements. As such, there is no assurance that the Proposed Secondary Listing will proceed to completion. The Company will provide further updates as and when there are material developments, in accordance with applicable laws and regulatory requirements.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares and to refrain from taking any action in respect of their shares which may be prejudicial to their interests. Shareholders and potential investors who are in doubt as to the action they should take should consult their stockbroker, bank manager, solicitor, accountant, tax adviser or other professional adviser.

Contacts

HomesToLife Ltd Contact:

12 Tai Seng Link, #03-01A,
GRC Centre, Singapore 534233
Email: Investor@homestolife.com

Investor Relations Inquiries:

Edelman Smithfield
Angela Hui
HomesToLife@edelmansmithfield.com

HOMESTOLIFE LTD AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(Currency expressed in United States Dollars (“US$”), except for number of shares)
 
  As of  
  December 31, 2025     June 30, 2026  
ASSETS
Current assets:
Cash and cash equivalents   $ 27,276,091     $ 17,941,401  
Restricted Cash     –       164,026  
Accounts receivables, net (including receivable from related parties of $5,763,509 and nil as of December 31, 2025 and June 30, 2026, respectively)     76,010,709       74,811,081  
Inventories, net     9,599,490       10,120,517  
Amounts due from related parties     7,026,092       –  
Deposit, prepayments and other receivables     5,853,470       6,741,958  
Total current assets     125,765,852       109,778,983  
 
Non-current assets:
Property, plant and equipment, net     4,354,206       5,884,250  
Right-of-use assets, net     7,363,312       7,528,176  
Restricted cash, non-current     –       111,136  
Investments in equity securities     –       1,000,000  
Other non-current assets     1,000,000       –  
Deferred tax asset, net     673,416       689,142  
Total non-current assets     13,390,934       15,212,704  
 
TOTAL ASSETS   $ 139,156,786     $ 124,991,687  
 
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable   $ 4,475,242     $ 4,587,814  
Accounts payable, related parties     74,890,989       63,749,207  
Customer deposits     1,195,989       1,188,847  
Accrued liabilities and other payables     6,065,126       6,697,637  
Short-term borrowings     10,389,094       7,263,986  
Lease liabilities, current     1,924,657       2,299,696  
Warranty liabilities     2,188,814       1,930,960  
Derivatives financial instruments     74,765       –  
Income tax payable     4,156,085       3,718,772  
Total current liabilities     105,360,761       91,436,919  
 
Long-term liabilities:
Provision for reinstatement cost     382,112       502,676  
Lease liabilities     5,572,603       5,377,461  
Total long-term liabilities     5,954,715       5,880,137  
 
TOTAL LIABILITIES     111,315,476       97,317,056  
 
Commitments and contingencies     –       –  
 
Shareholders’ equity:
Ordinary share, $0.0001 par value, 500,000,000 shares authorized,89,687,500 and 89,687,500 shares issued and outstanding as of December 31, 2025 and June 30, 2026, respectively     8,969       8,969  
Additional paid-in capital     37,179,424       37,179,424  
Accumulated other comprehensive loss     (12,111,193 )     (12,515,722 )
Retained earnings     2,764,110       3,001,960  
Total shareholders’ equity     27,841,310       27,674,631  
 
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY   $ 139,156,786     $ 124,991,687  
 

HOMESTOLIFE LTD AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(Currency expressed in United States Dollars (“US$”), except for number of shares)
 
  Six months ended June 30  
  2025     2026  
Revenues, net
From third parties   $ 170,117,861     $ 190,732,226  
From related parties     10,656,942       7,572,880  
      180,774,803       198,305,106  
Cost of goods sold     (130,942,258 )     (141,311,428 )
 
Gross profit     49,832,545       56,993,678  
 
Operating expenses:
Sales and distribution expenses     (31,092,110 )     (36,967,422 )
General and administrative expenses     (9,691,952 )     (10,327,858 )
Total operating expenses     (40,784,062 )     (47,295,280 )
 
Income from operations     9,048,483       9,698,398  
 
Other income (expense):
Interest expense     (730,372 )     (150,615 )
Interest income     16,246       19,193  
Government subsidies     16,950       23,385  
Foreign exchange gain (loss), net     4,293,633       (2,168,357 )
Net gain from related parties debt restructuring     1,460,543       –  
Professional fees on acquisition of HTL Marketing     (1,261,560 )     –  
Scrap sofa sale income     223,263       165,621  
Change in fair value of derivatives financial instruments     (753,243 )     74,765  
Sundry income(expense)     39,404       148,095  
Total other income (expense), net     3,304,864       (1,887,913 )
 
Income before income taxes     12,353,347       7,810,485  
 
Income tax expense     (2,329,272 )     (1,742,947 )
NET INCOME   $ 10,024,075     $ 6,067,538  
 
Other comprehensive income (loss):
– Foreign currency translation adjustments     1,368,175       (404,529 )
 
COMPREHENSIVE INCOME   $ 11,392,250     $ 5,663,009  
 
Weighted average number of ordinary shares:
Basic and diluted     89,687,500       89,687,500  
 
EARNINGS PER SHARE – BASIC AND DILUTED   $ 0.11     $ 0.07  
 

HOMESTOLIFE LTD AND SUBSIDIARIES
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Currency expressed in United States Dollars (“US$”), except for number of shares)
 
    Six months ended June 30, 2025  
    Retail Sales     Export Sales     Leather Trading     Corporate and
unallocated
    Total  
Revenues, net
From third party   $ 3,382,273     $ 166,459,189     $ 276,399     $ –     $ 170,117,861  
From related parties     –       1,550,023       9,106,919       –       10,656,942  
      3,382,273       168,009,212       9,383,318       –       180,774,803  
Cost of goods sold     (1,401,494 )     (120,526,294 )     (9,014,470 )     –       (130,942,258 )
 
Gross profit     1,980,779       47,482,918       368,848       –       49,832,545  
 
Operating expenses:
Sales and distribution expenses     (2,404,689 )     (28,634,760 )     (52,661 )     –       (31,092,110 )
General and administrative expenses     (906,968 )     (8,099,908 )     (3,025 )     (682,051 )     (9,691,952 )
Total operating expenses     (3,311,657 )     (36,734,668 )     (55,686 )     (682,051 )     (40,784,062 )
 
Operating income (loss)     (1,330,878 )     10,748,250       313,162       (682,051 )     9,048,483  
 
Other income (expenses):
Interest expense     (125,183 )     (394,423 )     (210,766 )     –       (730,372 )
Interest income     130       15,946       170       –       16,246  
Government subsidies     12,238       4,712       –       –       16,950  
Foreign exchange gain (loss), net     (9,647 )     4,292,067       6,215       4,998       4,293,633  
 
Net gain from related parties debt restructuring     –       –       –       1,460,543       1,460,543  
Professional fees on acquisition of HTL Marketing     –       (133,960 )     –       (1,127,600 )     (1,261,560 )
Scrap sofa sale income     –       223,263       –       –       223,263  
Sundry income (expense)     78,284       21,551       7       (60,438 )     39,404  
Change in fair value of derivatives financial instruments     –       (753,243 )     –       –       (753,243 )
Total other income (expenses), net     (44,178 )     3,275,913       (204,374 )     277,503       3,304,864  
 
Income (loss) before income taxes     (1,375,056 )     14,024,163       108,788       (404,548 )     12,353,347  
Income tax expense     –       (2,310,779 )     (18,493 )     –       (2,329,272 )
 
Segment income (loss)   $ (1,375,056 )   $ 11,713,384     $ 90,295     $ (404,548 )   $ 10,024,075  
 

  Six months ended June 30, 2026  
  Retail Sales     Export Sales     Leather Trading     Corporate and
unallocated
    Total  
Revenues, net
From third party   $ 5,313,821     $ 185,418,405     $ –     $ –     $ 190,732,226  
From related parties     –       874,947       6,697,933       –       7,572,880  
      5,313,821       186,293,352       6,697,933       –       198,305,106  
Cost of goods sold     (1,876,931 )     (133,106,987 )     (6,327,510 )     –       (141,311,428 )
 
Gross profit     3,436,890       53,186,365       370,423       –       56,993,678  
 
Operating expenses:
Sales and distribution expenses     (3,385,506 )     (33,560,786 )     (21,130 )     –       (36,967,422 )
General and administrative expenses     (694,444 )     (8,432,743 )     (1,969 )     (1,198,702 )     (10,327,858 )
Total operating expenses     (4,079,950 )     (41,993,529 )     (23,099 )     (1,198,702 )     (47,295,280 )
 
Operating income (loss)     (643,060 )     11,192,836       347,324       (1,198,702 )     9,698,398  
 
Other income (expenses):
Interest expense     –       (40,734 )     (109,881 )     –       (150,615 )
Interest income     465       18,421       307       –       19,193  
Government subsidies     15,685       7,700       –       –       23,385  
Foreign exchange gain (loss), net     (2,426 )     (2,319,989 )     163,712       (9,654 )     (2,168,357 )
Scrap sofa sale income     –       165,621       –       –       165,621  
Change in fair value of derivatives financial instruments     –       74,765       –       –       74,765  
Sundry income (expense)     89,747       (208,528 )     –       266,876       148,095  
Total other income (expenses), net     103,471       (2,302,744 )     54,138       257,222       (1,887,913 )
 
Income (loss) before income taxes     (539,589 )     8,890,092       401,462       (941,480 )     7,810,485  
Income tax expense     –       (1,674,699 )     (68,248 )     –       (1,742,947 )
 
Segment income (loss)   $ (539,589 )   $ 7,215,393     $ 333,214     $ (941,480 )   $ 6,067,538  
 

HOMESTOLIFE LTD AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Currency expressed in United States Dollars (“US$”), except for number of shares)
 
    Six months ended June 30,  
    2025     2026  
    USD     USD  
Net cash used in operating activities   (11,241,457 )   (8,266,135 )
Net cash used in investing activities   (557,755 )   (1,951,009 )
Net cash provided by financing activities   5,966,454     1,457,160  
Effect on exchange rate change on cash and cash equivalents, and restricted cash   1,043,524     (299,544 )
Net change in cash and cash equivalents, and restricted cash   (4,789,234 )   (9,059,528 )
BEGINNING OF PERIOD   24,860,621     27,276,091  
END OF PERIOD   20,071,387     18,216,563  

HONG KONG, Sept. 30, 2026 (GLOBE NEWSWIRE) — DarkIris Inc. (Nasdaq: DKI) (the “Company” or “DarkIris”), an innovative technology provider in the digital media and entertainment sector, today provided a business update highlighting recent progress in the development and global deployment of its flagship AI video production platform, Cine3.AI, as well as the Company’s North American expansion and interactive entertainment initiatives.

Advancing Cine3.AI for the “Cinema 3.0” Era

Following continued system development and optimization of its multimodal production workflows, DarkIris is advancing preparations for the global rollout of Cine3.AI, its professional AI-powered film production platform. The platform is currently undergoing pre-launch compliance review, testing and operational preparations ahead of its planned international launch.

DKI-1

DarkIris believes the global film and entertainment industry is entering what the Company refers to as the “Cinema 3.0” era, characterized by the increasing integration of generative AI technologies into professional content production workflows.

Cine3.AI integrates capabilities including high-fidelity visual generation, character consistency management and dynamic motion generation. The platform is designed for professional filmmakers, multi-channel network (“MCN”) operators and content production teams, providing tools that support multiple stages of the production process, including pre-visualization, shot rendering and post-production assistance.

DKI-2

Building on the Cine3.AI platform, DarkIris also intends to expand its participation across the film production value chain through AI-assisted production, co-production, and technology services for film, advertising, and other content projects.

Establishment of U.S. Subsidiary to Support North American Expansion

To further expand its presence in key entertainment markets and pursue growing commercial opportunities, DarkIris has established DarkIris US Inc., a wholly owned subsidiary in the United States.

The subsidiary is expected to serve as the Company’s operating hub in North America, with an initial focus on:

  • supporting the global commercialization of Cine3.AI and engagement with enterprise customers;
  • pursuing opportunities involving the acquisition and licensing of film and digital intellectual property (“IP”); and
  • providing AI-enabled production, co-production, and technology services for film, advertising, and other content projects in North America and international markets.

The U.S. subsidiary is expected to play a key role in DarkIris’ broader strategy to develop localized commercial capabilities in key entertainment markets worldwide.

Global Talent Initiative Reinforcing the Dual-Hub Model of Singapore and U.S. Operations

To support the commercialization of Cine3.AI and the Company’s international expansion, DarkIris has also initiated a global talent recruitment program centered on its strategic operations in Singapore and the United States.

The initial recruitment initiative will focus on senior positions in corporate administration, business development, IP operations and cross-border compliance. Through the development of localized business and operating teams, the Company intends to strengthen its engagement with film studios, advertising companies and digital entertainment participants across North America and the Asia-Pacific region.

Expanding into Interactive Entertainment Through “Quantum Project X”

In addition to its AI-powered film production technology, DarkIris is extending its digital entertainment ecosystem into interactive entertainment.

The Company is developing “Quantum Project X,” a historical strategy game.

Leveraging DarkIris’ internally developed AI visual production pipeline, Quantum Project X represents an extension of the Company’s core AI technology assets into interactive entertainment. The project is designed to explore opportunities to develop and commercialize IPs across both film and gaming formats.

DKI-3

DarkIris currently expects to complete development of Quantum Project X for open beta testing (“OBT”) and commence testing in Q2 2027. The timeline remains subject to the development process, testing results and other operational considerations.

Management Commentary

Mr. Zhifang Hong, Chief Executive Officer and Chairman of DarkIris, commented: “As we continue to build the technology foundation for ‘Cinema 3.0’ era, DarkIris is entering a new stage of development. By combining the core capabilities of Cine3.AI with localized production and commercial capabilities in North America, supported by our talent strategy across Singapore and the United States, we believe we are well positioned to pursue emerging opportunities across media and digital entertainment.”

Business Inquiries & Partnerships

To support the continued development of its global commercial ecosystem, DarkIris has established dedicated channels for the following areas of business cooperation:

Film Production & VFX Services
Email: production@cine3.ai

Cine3.AI Platform & Enterprise Partnerships
Cine3.AI Platform Website: https://cine3.ai/assets
Email: partner@cine3.ai

IP Licensing & Rights Acquisition
Email: partners@darkiris.com

Gaming & Interactive Co-Publishing
Email: bd@darkiris.com

About DarkIris Inc.

DarkIris Inc. (Nasdaq: DKI) is an innovative, growth-oriented public company focused on AI-driven digital media and content production technologies. Through advanced production capabilities, including its artificial intelligence platform, aideptus.com, the Company aims to provide creators, studios, and developers with generative AI solutions designed to streamline creative workflows and enhance digital content production experiences. For more information, please visit the Company’s website at www.darkiris.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performances, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks, including, but not limited to, the following: the Company’s ability to achieve its goals and strategies, the Company’s future business development and plans for future business development, including its financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, fluctuations in general economic and business conditions, the Company’s ability to comply with Nasdaq continued listing standards and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission (“SEC”). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, as well as its current reports on Form 6-K and other filings, all of which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For investor and media inquiries, please contact:

DarkIris Inc.
Investor Relations Department
Email: dki@darkiris.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1 646-932-7242
Email: investors@ascent-ir.com

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/4761dc83-7589-4e91-9a59-d331a0604ab2

https://www.globenewswire.com/NewsRoom/AttachmentNg/f81d6e3b-1a50-4476-8f20-e5a2c0017dd8

https://www.globenewswire.com/NewsRoom/AttachmentNg/ddb66c2c-04c2-4fa3-b4dc-6eba926dd449

SINGAPORE, Sept. 30, 2026 (GLOBE NEWSWIRE) — Ten-League International Holdings Limited (Nasdaq: TLIH) (the “Company” or “Ten-League”), a Singapore-based provider of turnkey project solutions, today announced its unaudited financial results for the six months ended June 30, 2026.

First Six Months of Fiscal Year 2026 Financial Highlights

  • Revenue was S$33.1 million (US$25.6 million) for the six months ended June 30, 2026, with engineering consultancy service income and rental income together contributing 45.4% of total revenue, compared with 18.5% in the same period last year, reflecting continued progress in the Company’s transition towards higher-value engineering solutions and recurring rental activities.
  • Growth businesses gained scale, with engineering consultancy service income increasing 669.4% to S$8.6 million (US$6.6 million) and rental income increasing 9.9% to S$6.4 million (US$5.0 million).
  • Gross profit margin was 24.0% for the six months ended June 30, 2026, an increase of 0.5 percentage points from 23.5% for the same period last year.
  • Net cash provided by operating activities remained strong at S$10.0 million (US$7.7 million), broadly consistent with the same period last year, supporting continued investment in the Company’s strategic priorities.
  • Financial position remained sound, with cash and cash equivalents of S$10.9 million (US$8.5 million) and shareholders’ equity increasing to S$18.5 million (US$14.3 million) as of June 30, 2026.

Mr. Jison Lim, Chief Executive Officer and Chairman of Ten-League, commented, “The first half of fiscal year 2026 demonstrated meaningful progress in reshaping our revenue mix towards engineering-led solutions and recurring rental activities amid evolving market conditions. Engineering consultancy services and rental together represented 45.4% of total revenue, compared with 18.5% in the same period last year. This shift reflects the increasing contribution from our strategic focus areas, including new energy infrastructure, automation and integrated engineering solutions. The delivery and acceptance of 30 electric prime movers (“ePM”) supported significant growth in engineering consultancy service income, while rental income continued to expand. Despite softer equipment sales, gross profit margin improved to 24.0%, demonstrating the resilience of our evolving business mix.”

Mr. Lim continued, “Looking ahead, we remain focused on advancing our strategic priorities across new energy infrastructure, automation, and engineering. We will continue to enhance our engineering capabilities and provide solutions that support customers’ operational efficiency and transition toward more sustainable equipment and infrastructure. At the same time, we remain committed to fostering strategic collaborations and strengthening our network of business partners. We believe these initiatives will position Ten-League to capture emerging opportunities as Singapore’s infrastructure and industrial sectors continue to evolve, while creating sustainable long-term value for our shareholders.”

First Six Months of Fiscal Year 2026 Unaudited Financial Results

Revenues

Total revenues were S$33.1 million (US$25.6 million) for the six months ended June 30, 2026. The revenue mix continued to shift towards engineering consultancy services and rental activities, which together contributed 45.4% of total revenue, compared with 18.5% for the same period last year. This change reflects the Company’s ongoing transition from primarily equipment sales towards a broader portfolio of engineering-led, new energy and recurring rental solutions.

  • Sales of heavy equipment and parts contributed 54.6% of total revenue for the six months ended June 30, 2026, compared with 81.5% for the same period last year, as contractors made greater use of rental equipment, delayed fleet replacement following significant fleet expansion over the preceding two years, and operated in a market with an oversupply of used equipment. Sales of heavy equipment and parts were S$18.1 million (US$14.0 million) for the six months ended June 30, 2026, a decrease of 41.1% from S$30.7 million for the same period last year.
  • Engineering consultancy service income was S$8.6 million (US$6.6 million) for the six months ended June 30, 2026, representing 25.9% of total revenue, compared with 3.0% for the same period last year. The increase of 669.4% was mainly due to the delivery and acceptance of 30 ePM and demonstrated the Company’s increasing commercialization of engineering and new energy capabilities.
  • Rental income increased 9.9% to S$6.4 million (US$5.0 million) for the six months ended June 30, 2026, and represented 19.5% of total revenue, compared with 15.5% for the same period last year. The increase reflected stronger rental demand amid economic uncertainty and high financing costs, reinforcing the contribution from recurring rental activities.

Cost of Revenue

Cost of revenue was S$25.1 million (US$19.4 million) for the six months ended June 30, 2026, a decrease of 12.8% from S$28.8 million for the same period last year.

Gross Profit

Gross profit was S$8.0 million (US$6.1 million) for the six months ended June 30, 2026, a decrease of 10.1% from S$8.8 million for the same period last year.

Gross profit margin was 24.0% for the six months ended June 30, 2026, an increase of 0.5 percentage points from 23.5% for the same period last year.

  • Gross profit margin for sales of heavy equipment and parts was 15.0% for the six months ended June 30, 2026, an increase of 0.2 percentage points from 14.8% for the same period last year. The increase was mainly due to better product mix and margin even though absolute sales value decreased.
  • Gross profit margin for engineering consultancy service income was 20.2% for the six months ended June 30, 2026, a decrease of 49.1 percentage points from 69.3% for the same period last year. The decrease was mainly due to the delivery and acceptance of 30 ePM.
  • Gross profit margin for rental income was 54.7% for the six months ended June 30, 2026, a decrease of 5.4 percentage points from 60.1% for the same period last year. The decrease was mainly due to higher depreciation expenses.

Selling and Distribution Expenses

Selling and distribution expenses were S$0.4 million (US$0.3 million) for the six months ended June 30, 2026, an increase of 21.7% from S$0.3 million for the same period last year. The increase was due to increase of staff salary and related costs.

General and Administrative Expenses

General and administrative expenses were S$5.2 million (US$4.0 million) for the six months ended June 30, 2026, a decrease from S$5.7 million for the same period last year.

Total Other Gain (Loss), Net

Total net other loss was S$0.1 million (US$0.08 million) for the six months ended June 30, 2026, compared to a total net other gain of S$0.1 million for the same period last year.

Net Income

Net income was S$1.7 million (US$1.3 million) for the six months ended June 30, 2026, compared to S$2.4 million for the same period last year.

Basic and Diluted Income per Share

Basic and diluted income per share was S$0.59 (US$0.46) for the six months ended June 30, 2026, compared to S$0.86 for the same period last year.

Financial Condition

As of June 30, 2026, the Company had cash and cash equivalents of S$10.9 million (US$8.5 million), compared to S$10.7 million as of December 31, 2025.

Net cash provided by operating activities was S$10.0 million (US$7.7 million) for the six months ended June 30, 2026, compared to S$10.0 million for the same period last year.

Net cash used in investing activities was S$7.1 million (US$5.5 million) for the six months ended June 30, 2026, compared to net cash provided by investing activities of S$0.2 million for the same period last year.

Net cash used in financing activities was S$2.6 million (US$2.0 million) for the six months ended June 30, 2026, compared to S$5.7 million for the same period last year.

Exchange Rate Information

This announcement contains translations of certain Singapore dollar amounts into U.S. dollars for the convenience of the reader. Translations of amounts from Singapore dollars into U.S. dollars have been made at the exchange rate of S$1.2941 = US$1.00, which was the foreign exchange rate on June 30, 2026 as reported by the Board of Governors of the Federal Reserve System in its weekly release on July 6, 2026.

About Ten-League International Holdings Limited

Ten-League International Holdings Limited is a Singapore-based provider of turnkey project solutions. The Company’s business primarily consists of sales of heavy equipment and parts, heavy equipment rental and provision of engineering consultancy services to port, construction, civil engineering and underground foundation industries. The equipment is organized into four categories based on their functions and application scenarios: foundation equipment, hoist equipment, excavation equipment and port machinery. The Company also provides value-added engineering solutions under engineering consultancy services with the aim to address potential safety issues, enhance reliability and productivity and allow for customers to evaluate the performance of the equipment, the quality of the work completed and the progress of their projects. Ten-League’s mission is to provide high-quality equipment, value-added engineering solutions as well as maintenance and repair through continuous adaptation and application of new technologies. For more information, please visit the Company’s website: https://ir.ten-league.com.sg/.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “believe”, “plan”, “expect”, “intend”, “should”, “seek”, “estimate”, “will”, “aim” and “anticipate” or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission (“SEC”). Readers are cautioned not to place undue reliance on these forward-looking statements and are advised to consider the factors listed above together with the additional factors under the heading “Risk Factors” in the Company’s Annual Reports on Form 20-F, as may be supplemented or amended by the Company’s Reports of a Foreign Private Issuer on Form 6-K.

For investor and media inquiries, please contact:

Ten-League International Holdings Limited
Investor Relations Department
Email: ir@ten-league.com.sg

Ascent Investor Relations LLC
Tina Xiao
Phone: +1 646-932-7242
Email: investors@ascent-ir.com

TEN-LEAGUE INTERNATIONAL HOLDINGS LIMITED AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amount in thousands, except for share and per share data, or otherwise noted)
 
        As of Dec 31,     As of Jun 30,     As of Jun 30,  
    Note   2025     2026     2026  
        S$’000     S$’000     US$’000  
        (Audited)     (Unaudited)     (Unaudited)  
                       
ASSETS                            
Current assets:                            
Cash and cash equivalents         10,684       10,938       8,452  
Accounts receivable, net         14,410       12,584       9,724  
Contract assets         79       650       502  
Inventories         15,761       6,728       5,199  
Deposits, prepayments and other receivables         2,996       2,157       1,667  
Total current assets         43,930       33,057       25,544  
                             
Non-current assets:                            
Property and equipment, net         33,137       35,807       27,670  
Right-of-use assets         11       9       7  
Other receivables         304       338       261  
Total non-current assets         33,452       36,154       27,938  
                             
TOTAL ASSETS         77,382       69,211       53,482  
                             
LIABILITIES AND SHAREHOLDERS’ EQUITY                            
Current liabilities:                            
Accounts payable and accrued liabilities         11,488       4,684       3,620  
Amounts due to related parties         14,472       13,878       10,723  
Bank borrowings         16,953       14,742       11,392  
Lease liabilities         6,606       7,041       5,441  
Income tax payable         993       1,038       802  
Total current liabilities         50,512       41,383       31,978  
                             
Long-term liabilities:                            
Lease liabilities         7,558       6,759       5,223  
Deferred tax liabilities         2,613       2,613       2,019  
Total long-term liabilities         10,171       9,372       7,242  
                             
TOTAL LIABILITIES         60,683       50,755       39,220  
                             
Commitments and contingencies         –       –       –  
                             
Shareholders’ equity                            
Ordinary share, par value US$0.00025, 2,000,000,000 shares authorized, 2,940,451 ordinary shares issued and outstanding**         -*       5,778       4,465  
Additional paid-in capital         5,778       –       –  
Retained earnings         10,921       12,665       9,787  
Accumulated other comprehensive income         -*       13       10  
                             
Total shareholders’ equity         16,699       18,456       14,262  
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY         77,382       69,211       53,482  
                             

* – denotes amount less than $’000.
** – On April 13, 2026, the Company effected a 1-for-10 reverse share spilt, whereby every ten (10) issued and outstanding ordinary shares were consolidated into one (1) ordinary share, with a corresponding increase in par value from $0.000025 to $0.00025 per share. All share and per share information presented in these financial statements have been retrospectively adjusted, where applicable, to reflect this share consolidation. The consolidation did not affect total shareholders’ equity. On May 1, 2026, 16 ordinary shares were issued for no consideration to shareholders whose fractional shares were rounded up to the nearest whole share following the reverse share split.

TEN-LEAGUE INTERNATIONAL HOLDINGS LIMITED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(Amount in thousands, except for share and per share data, or otherwise noted)
 
        Six Months ended June 30,  
    Note   2025     2026     2026  
        S$’000     S$’000     US$’000  
          (Unaudited)       (Unaudited)       (Unaudited)  
                             
Revenues, net         37,687       33,095       25,574  
                             
Cost of revenue         (28,840 )     (25,140 )     (19,427 )
                             
Gross profit         8,847       7,955       6,147  
                             
Operating cost and expenses:                            
Selling and distribution         (306 )     (381 )     (294 )
General and administrative         (5,661 )     (5,223 )     (4,037 )
Total operating cost and expenses         (5,967 )     (5,604 )     (4,331 )
                             
Profit from operations         2,880       2,351       1,816  
                             
Other income (expense):                            
(Loss)/Gain from disposal of plant and equipment         (30 )     1       1  
Interest income         94       186       144  
Interest expense         (430 )     (377 )     (291 )
Government grant         5       5       4  
Exchange gain         251       –       –  
Other income         204       87       67  
Total other gain/(loss), net         94       (98 )     (75 )
                             
Income before income taxes         2,974       2,253       1,741  
                             
Income tax expense         (591 )     (509 )     (393 )
                             
NET INCOME         2,383       1,744       1,348  
                             
OTHER COMPREHENSIVE INCOME                    
Foreign currency translation adjustments   –       13       10  
                             
COMPREHENSIVE INCOME         2,383       1,757       1,358  
                             
Net income per share                            
Basic and diluted         0.86       0.59       0.46  
                             
Weighted average number of ordinary shares outstanding                            
Basic and diluted*         2,779,650       2,940,440       2,940,440  
                             

* – On April 13, 2026, the Company effected a 1-for-10 reverse share spilt, whereby every ten (10) issued and outstanding ordinary shares were consolidated into one (1) ordinary share, with a corresponding increase in par value from $0.000025 to $0.00025 per share. All share and per share information presented in these financial statements have been retrospectively adjusted, where applicable, to reflect this share consolidation. The consolidation did not affect total shareholders’ equity. On May 1, 2026, 16 ordinary shares were issued for no consideration to shareholders whose fractional shares were rounded up to the nearest whole share following the reverse share split.

TEN-LEAGUE INTERNATIONAL HOLDINGS LIMITED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amount in thousands, except for share and per share data, or otherwise noted)
 
    Six Months ended June 30,  
    2025     2026     2026  
    S$’000     S$’000     US$’000  
    (Unaudited)     (Unaudited)     (Unaudited)  
                   
Cash flows from operating activities:                        
Net income     2,383       1,744       1,348  
Adjustments to reconcile net income to net cash provided by operating activities                        
Depreciation of property and equipment     2,241       2,614       2,020  
Depreciation of right-of-use assets     594       2       2  
Loss on disposal of property and equipment     30       –       –  
                         
Change in working capital:                        
Accounts receivable     1,582       2,525       1,951  
Contract assets     (342 )     (571 )     (441 )
Inventories     2,791       10,991       8,493  
Related parties     161       (594 )     (459 )
Accounts payable and accrued liabilities     122       (6,804 )     (5,258 )
Income tax payable     463       45       35  
Net cash provided by operating activities     10,025       9,952       7,691  
                         
Cash flows from investing activities:                        
Proceeds from disposal of property and equipment     47       –       –  
Repayment from finance lease receivables     371       436       337  
Purchase of property and equipment     (236 )     (7,572 )     (5,851 )
Net cash provided by/(used in) investing activities     182       (7,136 )     (5,514 )
                         
Cash flows from financing activities:                        
Proceeds of bank borrowings     679       1,484       1,147  
Deferred IPO expenses     (923 )     –       –  
Repayment of bank borrowings     (266 )     –       –  
Principal repayment of lease liabilities     (4,622 )     (4,057 )     (3,135 )
Payment of deferred financing costs     (597 )     (2 )     (2 )
Net cash used in financing activities     (5,729 )     (2,575 )     (1,990 )
                         
Effect on exchange rate change on balances held in foreign currency     –       13       9  
                         
Net change in cash and cash equivalent     4,478       254       196  
                         
BEGINNING OF PERIOD     686       10,684       8,256  
                         
END OF PERIOD     5,164       10,938       8,452  
                         
SUPPLEMENTAL CASH FLOW INFORMATION:                        
Cash paid for income taxes     127       464       359  
Cash paid for interest     430       377       291  
Cash received from finance lease receivable interest     (94 )     (185 )     (143 )
Operating lease asset obtained in exchange for operating lease obligations     –       –       –  

DELAWARE, Ohio, Sept. 30, 2026 (GLOBE NEWSWIRE) — Greif, Inc. (NYSE: GEF, GEF.B), a global leader in industrial packaging products and services, announced today it will report the company’s 2026 fourth quarter financial results after the market closes on Tuesday, November 3, 2026. A conference call will be held on Wednesday, November 4, 2026, at 8:00 a.m. ET to discuss the quarter results.

Greif will provide conference call slides in combination with the earnings press release. The conference call will include management’s prepared remarks and a question and answer session.

Participants may access the call using the following online registration link. Registrants will receive a confirmation containing dial in details and a unique conference call code for entry. Phone lines will open at 7:30 a.m. ET. A digital replay of the conference call will be available two hours following the call on the company’s web site at http://investor.greif.com.

Webcast Details
Title: Greif, Inc. Q4 2026 Earnings Conference Call
URL: https://edge.media-server.com/mmc/p/dsqxmnhz/lan/en

About Greif

Founded in 1877, Greif is a global leader in performance packaging located in over 35 countries. The company delivers trusted, innovative, and tailored solutions that support some of the world’s most demanding and fastest-growing industries. With a commitment to legendary customer service, operational excellence, and global sustainability, Greif packages life’s essentials – and creates lasting value for its colleagues, customers, and other stakeholders. Learn more about the company’s Customized Polymer, Sustainable Fiber, Durable Metal, and Innovative Closure Solutions at www.greif.com and follow Greif on Instagram and LinkedIn.

Contact:

Bill D’Onofrio
614-499-7233
bill.donofrio@greif.com

U.S. District Court for the Southern District of Florida denies motions to dismiss filed by all defendants, permitting Genius Group’s Racketeer Influenced and Corrupt Organizations Act (“RICO”) claims to proceed.

The Company’s lawsuit seeking treble damages of over $750 million against Michael Moe, Peter Ritz, John Clayton, and Michael Carter.

SINGAPORE, Sept. 30, 2026 (GLOBE NEWSWIRE) — Genius Group Limited (NYSE American: GNS) (“Genius Group”, “GNS” or the “Company”), a leading AI-powered education group, is announcing today that on September 27, 2026, the United States District Court for the Southern District of Florida denied the motions to dismiss filed in the Company’s lawsuit against defendants Michael Moe, Peter Ritz, John Clayton, and Michael Carter.

The Court’s denial of the defendants’ motions confirms that the Company has sufficiently alleged claims under the Federal and Florida State iterations of the Racketeer Influenced and Corrupt Organizations (RICO) Act, pursuant to which the Company seeks nearly $1 billion in damages.

The Company’s complaint alleges that the defendants used LZG International, Inc. (“LZGI”) to perpetrate an unlawful scheme through interstate fraudulent wire and mail transactions and to the detriment of the Company (as well as other issuers). Among other things, the Company’s complaint alleges that the defendants made false representations to deceive the Company into entering the asset purchase agreement with LZGI, which enabled the defendants to extort millions of dollars in cash and stock from the Company, and—after the Company evicted Peter Ritz and Michael Moe from their positions within Genius Group—defendants used LZGI to retaliate against the Company by seeking a preliminary injunction during early-2025.

The favorable ruling is the Company’s latest victory in the protracted battle relating to LZGI and joins, most notably, the Company prevailing in the ICC Arbitration against LZGI, pursuant to which Genius was awarded the return of the 7.4 million shares of its common stock and approximately $8 million in monetary relief.

Roger James Hamilton, CEO of Genius Group, said “This is a very positive ruling in favor of the Company. I’d like to acknowledge Mark R. Basile, Esq. and his team at The Basile Law Firm P.C., whose expertise in RICO litigation and securities violations has been instrumental in protecting Genius Group and its shareholders. From winning the ICC arbitration, to vacating the injunction at the Second Circuit, to defeating all motions to dismiss, Mark and his team have delivered results that speak for themselves. We look forward to discovery and to holding the defendants fully accountable.”

The Company remains committed to vigorously litigating its legal interests in the Southern District of Florida against the defendants with a view towards rectifying all the harm the Company has suffered at their hands.

About Genius Group

Genius Group (NYSE: GNS) is a global education group delivering AI powered, education and acceleration solutions for the future of work. Genius Group serves 6 million users in over 100 countries through its Genius City model and online digital marketplace of AI training, AI tools and AI talent. It provides personalized, entrepreneurial AI pathways combining human talent with AI skills and AI solutions at the individual, enterprise and government level. To learn more, please visit geniusgroup.ai

Forward-Looking Statements

Statements made in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements can be identified by the use of words such as “may,” “will”, “plan,” “should,” “expect,” “anticipate,” “estimate,” “continue,” or comparable terminology. Such forward-looking statements are inherently subject to certain risks, trends and uncertainties, many of which the Company cannot predict with accuracy and some of which the Company might not even anticipate and involve factors that may cause actual results to differ materially from those projected or suggested. Readers are cautioned not to place undue reliance on these forward-looking statements and are advised to consider the factors listed above together with the additional factors under the heading “Risk Factors” in the Company’s Annual Reports on Form 20-F, as may be supplemented or amended by the Company’s Reports of a Foreign Private Issuer on Form 6-K. The Company assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise. No information in this press release should be construed as any indication whatsoever of the Company’s future revenues, results of operations, or stock price.

Contacts
For enquiries, contact investor@geniusgroup.ai

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.